OBJECTIVES The aim of this study was to establish the prevalence of sarcopenia and associated factors in elderly patients with type 2 diabetes mellitus (DM) according to 2010 (EWGSOP1) and 2018 (EWGSOP2) European consensus. DESIGN Cross-sectional study. PARTICIPANTS Elderly outpatients ≥60 years with type 2 DM and able to walk were recruited at the DM ambulatory care center of a public hospital in Porto Alegre from 2017 to 2018. MATERIALS AND METHODS The diagnosis of sarcopenia was performed according to EWGSOP1 and EWGSOP2. Muscle mass (MM) was assessed using bioelectrical impedance (BIA). Muscle strength (MS) was assessed using the handgrip strength (HS) test and physical performance (PP) by timed-up-and-go (TUG) test. RESULTS We included 242 patients with 68.3 ± 5.6 years, 54% women, 78% white, DM duration 14(8-22) years, BMI 29.5 ± 4.5 kg/m2, and HbA1c 7.8 ± 1.5%. Overall prevalence of sarcopenia was 21%. In EWGSOP1 it was 16.9%. The GLM Poisson model was used to assess sarcopenia. Male sex increased the prevalence of sarcopenia by 33% (3.330 [1.747-6.350]; p < .001), and walking >5401 steps/day had a protective effect of 70% for the prevalence of sarcopenia (0.306 [0.127-0.739]; p = .029). Finally, age had an impact of 6% on prevalence of sarcopenia (1.06 [1.015-1.108]; p = .009) according to EWGSOP1. On the other hand, the prevalence was 7%, women had more sarcopenia (88%), and BMI was lower in the sarcopenic group when defined according to EWGSOP2. CONCLUSIONS The prevalence of sarcopenia was more than double when comparing EWGSOP1 (16.9%) and EWGSOP2 (7%). We believe that the difference in prevalence is due to modifications in MM and MS criteria. According to EWGSOP1, walking may have protective role in the prevalence of sarcopenia in elderly type 2 DM individuals.

中文翻译：

---

根据2010年和2018年欧洲共识（EWGSOP），老年2型糖尿病患者的肌肉减少症患病率和相关因素的差异。

目的本研究旨在根据欧洲共识（2010年（EWGSOP1）和2018年（EWGSOP2））确定老年2型糖尿病（DM）患者的少肌症及其相关因素的患病率。设计横断面研究。研究对象2017年至2018年，在阿雷格里港一家公立医院的DM门诊医疗中心招募了年龄≥60岁且患有2型DM且能够行走的老年门诊患者。材料与方法根据EWGSOP1和EWGSOP2进行肌少症的诊断。使用生物电阻抗（BIA）评估肌肉质量（MM）。使用握力（HS）测试和物理性能（PP）通过定时走（TUG）测试评估肌肉强度（MS）。结果我们纳入了242例68.3±5.6岁的患者，54％的女性，78％的白人，DM持续时间14（8-22）岁，BMI 29.5±4。5 kg / m2，HbA1c 7.8±1.5％。肌肉减少症的总体患病率为21％。在EWGSOP1中，这一比例为16.9％。GLM Poisson模型用于评估肌肉减少症。男性将肌肉减少症的患病率提高了33％（3.330 [1.747-6.350]； p <.001），每天步行> 5401步对肌肉减少症的患病率具有70％的保护作用（0.306 [0.127-0.739] ； p = .029）。最后，根据EWGSOP1，年龄对肌肉减少症的患病率有6％的影响（1.06 [1.015-1.108]； p = .009）。另一方面，根据EWGSOP2的定义，少肌症组的患病率为7％，女性少肌症（88％）和BMI较低。结论当比较EWGSOP1（16.9％）和EWGSOP2（7％）时，肌肉减少症的患病率是两倍多。我们认为患病率的差异是由于MM和MS标准的修改引起的。